Osimertinib
astrazeneca
[]
 #esmo22 points out that the dfs hr is on par with the original analysis but the shape of the curves is different, especially for stage ii/iii 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him